Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh

Ashraful Islam Khan, Mohammad Ali, Fahima Chowdhury, Amit Saha, Iqbal Ansary Khan, Arifuzzaman Khan, Afroza Akter, Muhammad Asaduzzaman, Md Taufiqul Islam, Alamgir Kabir, Young Ae You, Nirod Chandra Saha, Alejandro Cravioto, John D Clemens, Firdausi Qadri, Ashraful Islam Khan, Mohammad Ali, Fahima Chowdhury, Amit Saha, Iqbal Ansary Khan, Arifuzzaman Khan, Afroza Akter, Muhammad Asaduzzaman, Md Taufiqul Islam, Alamgir Kabir, Young Ae You, Nirod Chandra Saha, Alejandro Cravioto, John D Clemens, Firdausi Qadri

Abstract

Background: Pregnant women are vulnerable to complications of cholera. Killed oral cholera vaccines (OCV) are not recommended for pregnant women though there is no evidence of harmful effects during pregnancy. We evaluated the effect of a killed OCV, Shanchol™, on pregnancy outcomes during an effectiveness trial of the vaccine in urban Bangladesh.

Methodology: Individuals ⩾1year were invited to participate in the trial, conducted in 2011 in Dhaka, Bangladesh. Pregnancy by history was an exclusion criterion and all women of reproductive age (15-49years) were verbally questioned about pregnancy at enrollment and prior to vaccination. Out of 48,414 women of reproductive age 286 women received the OCV unknowingly while pregnant. Out of these, we could recruit 69 women defined as exposed to OCV. Accordingly, we selected 69 pregnant women randomly from those who did not take the OCV (non-exposed to OCV). We evaluated adverse pregnancy outcome (spontaneous miscarriages, still births, or congenital malformations) between those who were exposed to OCV and those who were not exposed to OCV.

Results: About 16% of pregnant women exposed to OCV had pregnancy loss, as compared to 12% of unvaccinated pregnant women (P=0.38). One congenital anomaly was observed and occurred in women non-exposed to OCV group. Models that adjusted for baseline characteristics that were unbalanced between the exposed and non-exposed groups, revealed a no elevation of risk of adverse pregnancy outcomes in vaccinees versus non-vaccinees (Adj. OR (95% CI): 0.45 (0.11-1.88).

Conclusions: No excess of adverse fetal outcomes associated with receipt of OCV was observed in this study.

Trial registration: Clinical Trials.gov number NCT01339845.

Keywords: Oral cholera vaccine; Pregnancy; Shanchol™; Vaccination.

Copyright © 2017. Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Assembling of the exposed and non-exposed to oral cholera vaccine (OCV) for the study.

References

    1. Glass R.I. Endemic cholera in rural Bangladesh, 1966–1980. Am J Epidemiol. 1982;116(6):959–970.
    1. Diop S. Cholera and pregnancy: epidemiological, clinical, and evolutionary aspects. Medecine et maladies infectieuses. 2007;37(12):816–820.
    1. Hirschhorn N., Chowdhury A.A., Lindenbaum J. Cholera in pregnant women. Lancet. 1969;293(7608):1230–1232.
    1. Ayangade O. The significance of cholera outbreak in the prognosis of pregnancy. Int J Gynecol Obstetr. 1981;19(5):403–407.
    1. WHO, WHO position paper. Wkly Epidemiol Rec, 2010:85(13): 117–28.
    1. Grout L. Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine in Guinea: a retrospective cohort study. PLoS Negl Trop Dis. 2015;9(12):e0004274.
    1. Hashim R. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis. 2012;6(7):e1743.
    1. Sur D.K., Wallis D.H., O’Connell T.X. Vaccinations in pregnancy. Am Fam Physician. 2003;68(2):299–304.
    1. Khan I.A. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine. 2013;31(51):6058–6064.
    1. Qadri F. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet. 2015;386(10001):1362–1371.
    1. Ali M. Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania. Bull World Health Organ. 2010;88(7):556–559.
    1. Mahalanabis D. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE. 2008;3(6):e2323.
    1. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
    1. Peduzzi P. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–1379.
    1. Patorno E. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score–based confounding adjustments. Epidemiology. 2014;25(2):268–278.
    1. WHO, Technical Note: evidence of the risks and benefits of vaccinating pregnant women with WHO pre-qualified cholera vaccines during mass campaigns; 2016.
    1. CHOLERA, S., Cholera and the use of oral cholera vaccines in pregnant women; 2016.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren